• HOME
• ABOUT US
  • Company Profile
  • CRO's & Pharmaceutical Companies
• COMPANY BIOS
  • Jeff Stein
  • David M. Radin, MD
  • Judith Dalgin
  • Svetlana Konnov, LPN
  • Betsy Kempner, RN
  • Patrick Brew, MD, RN
  • Tulie Brew, MD
  • Anju Sherstha, MD
• CURRENT TRIALS
  • Cholesterol
  • Contraception
  • Gout / Acute Coronary Syndrome
  • Myocardial Infarction
  • Opiate-Induced Constipation
  • Osteoarthritis
    of the Knee
• CONDITIONS
• CONTACT US
  • Clinical Trial
    Contact Form
  • Locations

Myocardial Infarction

Stamford Therapeutics Consortium is currently conducting a study on
Myocardial Infarction sponsored by AstraZeneca.

Summary: This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

For More Information Please Contact:
Judy Dalgin (Site Manager)
email: jdalgin@stctrials.com
telephone: 203-325-8529


Eligibility:

• Ages Eligible for Study: 50 Years and older

• Genders Eligible for Study: Both

• Accepts Healthy Volunteers: No


Inclusion Criteria:

• Person who had a heart attack within 1 - 3 years ago and at least one additional risk factor: Age ≥ 65 years old, Diabetes requiring medication, Documented history of 2nd prior MI (>1 year ago). Angiographic evidence of multivessel CAD, and / or Chronic, non-end stage renal dysfunction.

• Females of child-bearing potential must have a negative pregnancy test at enrollment

• Persons who are currently taking aspirin between 75 and 150 mg once daily


Exclusion Criteria:

• Persons who are being treated with agents inhibiting blood clotting if the agent cannot be stopped at study start

• Persons who have planned coronary, cerebrovascular, or peripheral arterial Revascularization (invasive surgery) at study start